RESEARCHER PROFILE
Professor Ernst J. Wolvetang
Australian Institute for Bioengineering and Nanotechnology
The University of Queensland
Australia
Professor Ernst Wolvetang obtained his PhD from the University of Amsterdam, continued his post-doctoral training at the Monash Institute for Reproduction and Development, before joining the Australian Stem Cell Centre.
In 2008 he was recruited to the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland (UQ). He currently heads the Stem Cell Engineering Laboratory and directs the Australian Organoid Facility at UQ as well as the Phenomics Australia NNAT node at UQ.
He is a leader in the derivation, genome editing and disease modelling with human induced pluripotent stem cell and organoids derived from these. Professor Wolvetang is known as our “Mr Organoid” for his trailblazing approach to this exciting field of medical research. He is a pioneer in the field of pluripotent stem cell biology, whose frank and colourful turn of phrase underscores the passion he has for his work.
Professor Wolvetang was among the first to bring the first human embryonic stem cells to Queensland, with his Wolvetang Group at the AIBN now renowned for its work with organoids: growing them, studying them, and using them to try and understand diseases and human development.
Using cutting edge technology, Professor Wolvetang designs and grows organoids both for their own work and for labs across the country, coaxing pluripotent stem cells or tissue samples into 3D structures that mimic the function and architecture of real brains, livers, kidneys, spinal cords, and intestines.
Crucially, Professor Wolvetang says organoids could one day negate the need for animal models, as they can be designed to replicate what is happening inside an individual patient, offering researchers a unique opportunity to study personalised responses to new treatments.
He says this could shave years off the drug development process and – ultimately – the time between diagnosing a problem and delivering the solution.
“Once we demonstrate the power and accuracy of this approach for one genetic disease, it could open the door for testing of other gene therapies for a range of genetic neurological conditions.”, says Professor Wolvetang.
-
Exercise therapy for metabolic dysfunction-associated steatotic liver disease
Dr Shelley Keating is a Senior Lecturer in Clinical Exercise Physiology and Accredited Exercise Physiologist from the School of Human Movement and Nutrition Sciences at the University of Queensland. With a strong grounding in exercise metabolism and body composition, Dr Keating’s research centres on the utility of exercise as a therapy for obesity and related cardiometabolic conditions, notably metabolic dysfunction-associated steatotic liver disease (MASLD).
-
Treatment pathways for chronic plantar heel pain
Jason Rogers is a Tasmanian physiotherapist clinician-researcher with a longstanding interest in improving musculoskeletal foot and ankle conditions. He completed his PhD at the Menzies Institute for Medical Research at the University of Tasmania in 2022 investigating the clinical and imaging factors associated with a common foot complaint known as chronic plantar heel pain.
-
Risk factors and prevention of respiratory infections and infectious diseases in children
A/Prof Hannah Moore OAM is an infectious disease epidemiologist; Co-Head of the Infectious Disease Epidemiology team within the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia and Associate Professor at the School of Population Health, Curtin University in Western Australia.
A/Prof Moore has been awarded more than $19M in competitive research grants, co-authored more than 140 papers, was TEDxPerth 2018 speaker, recipient of a WA Young Tall Poppy Award (2013) and the WA Premiers Science Early Career Scientist Award (2015). In 2024, she was honoured with a Medal of the Order of Australia for her service to epidemiology as a researcher.
